• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Definitive Healthcare Corp.

    5/9/25 12:25:52 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology
    Get the next $DH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    DEFINITIVE HEALTHCARE CORP

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    24477E103

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    24477E103


    1Names of Reporting Persons

    THE GOLDMAN SACHS GROUP, INC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,692,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,693,876.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,711,896.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    CUSIP No.
    24477E103


    1Names of Reporting Persons

    GOLDMAN SACHS & CO. LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,692,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,693,876.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,711,896.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    BD, OO, IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    DEFINITIVE HEALTHCARE CORP
    (b)Address of issuer's principal executive offices:

    492 Old Connecticut Path Suite 401, FRAMINGHAM,X1,01701
    Item 2. 
    (a)Name of person filing:

    THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
    (b)Address or principal business office or, if none, residence:

    The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
    (c)Citizenship:

    THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    24477E103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    See the response(s)to Item 11 on the attached cover page(s).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit (99.2)
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    THE GOLDMAN SACHS GROUP, INC.
     
    Signature:Name: AMEEN SOETAN
    Name/Title:Attorney-in-fact
    Date:04/02/2025
     
    GOLDMAN SACHS & CO. LLC
     
    Signature:Name: AMEEN SOETAN
    Name/Title:Attorney-in-fact
    Date:04/02/2025
    Exhibit Information

    EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $ per share, of DEFINITIVE HEALTHCARE CORP and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 04/02/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

    Get the next $DH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DH

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    12/20/2024$5.00Equal-Weight
    Stephens
    9/17/2024$7.00Buy
    BTIG Research
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    5/8/2024$11.50 → $9.00Overweight → Equal-Weight
    Morgan Stanley
    1/17/2024Buy → Hold
    Needham
    1/5/2024Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $DH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      11/12/24 11:54:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      10/3/24 9:08:57 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Definitive Healthcare Corp. (Amendment)

      SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      2/14/24 4:00:33 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Definitive Healthcare Corp.

      SCHEDULE 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      5/9/25 12:25:52 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 10-Q filed by Definitive Healthcare Corp.

      10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:22:09 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:10:28 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Financials

    Live finance-specific insights

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

      FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

      2/27/25 4:05:53 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

      FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of

      4/4/25 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Leadership Updates

    Live Leadership Updates

    See more
    • Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

      FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

      5/28/24 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

      Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

      11/28/23 5:00:00 PM ET
      $DH
      $GDRX
      Computer Software: Prepackaged Software
      Technology
      EDP Services
    • Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

      FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

      10/5/23 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Booth Richard Douglas covered exercise/tax liability with 7,873 shares, decreasing direct ownership by 1% to 652,630 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:10 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • EXECUTIVE CHAIRMAN Krantz Jason Ronald covered exercise/tax liability with 18,795 shares, decreasing direct ownership by 2% to 1,106,362 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:14 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • CHIEF OPERATING OFFICER Shamsuddin Kate Marie covered exercise/tax liability with 4,595 shares, decreasing direct ownership by 0.65% to 699,902 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:11 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Definitive Healthcare downgraded by BTIG Research

      BTIG Research downgraded Definitive Healthcare from Buy to Neutral

      5/9/25 8:41:31 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare downgraded by Barclays with a new price target

      Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

      1/13/25 7:41:23 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Stephens initiated coverage on Definitive Healthcare with a new price target

      Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00

      12/20/24 7:31:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology